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Abstract In this independent, multicentre post-marketing study we directly compared the effectiveness of
natalizumab (NTZ), fingolimod (FNG) and self-injectable drugs (INJ), in non-responders to first
immunomodulating treatment and in highly active treatment-naïve patients with multiple sclerosis. As
main outcome measure we considered the proportions of patients with no evidence of disease activity
(NEDA-3), defined as absence of relapses, disability worsening and radiological activity. A total of 567
non-responders to interferon beta (IFNB) or glatiramer acetate (GA) [dataset A] and 216 highly active
treatment-naïves [dataset B] were followed up to 24 months from the beginning of NTZ, FNG or INJ, i.e.
switching from IFNB to GA or viceversa (in the case of non-responders) or starting high-dose IFNB (in the
case of highly active treatment-naives). Propensity score matching in a 1:1:1 ratio was used to select only
patients with similar baseline characteristics, retaining 330 and 120 patients in dataset A and B,
respectively. In dataset A, the 24-month proportion with NEDA-3 was greater in both NTZ group (67%)
and FNG group (42%) than in INJ group (35%) (p ≤ 0.016); however, NTZ was superior to FNG in
promoting the attainment of NEDA-3 status (p = 0.034). In dataset B, the 24-month proportion with
NEDA-3 was greater in NTZ group (75%) and FNG group (67%) than in INJ group (40%), but the small
cohort sizes most likely prevented the detection of any statistically significant difference. Our study
provides real-world evidence that NTZ was more effective than both FNG and INJ in non-responders,
while it could seem that, in highly active treatment-naives, NTZ was as effective as FNG and both were
superior to INJ.
Keywords (separated by '-') Multiple sclerosis - Propensity score - NEDA - Disease-modifying drugs
Footnote Information Electronic supplementary material The online version of this article (doi:10.1007/s00415-016-8343-5)
contains supplementary material, which is available to authorized users.
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18 multiple sclerosis. As main outcome measure we consid-
19 ered the proportions of patients with no evidence of disease
20 activity (NEDA-3), defined as absence of relapses, dis-
21 ability worsening and radiological activity. A total of 567
22non-responders to interferon beta (IFNB) or glatiramer
23acetate (GA) [dataset A] and 216 highly active treatment-
24naı¨ves [dataset B] were followed up to 24 months from the
25beginning of NTZ, FNG or INJ, i.e. switching from IFNB
26to GA or viceversa (in the case of non-responders) or
27starting high-dose IFNB (in the case of highly active
28treatment-naives). Propensity score matching in a 1:1:1
29ratio was used to select only patients with similar baseline
30characteristics, retaining 330 and 120 patients in dataset A
31and B, respectively. In dataset A, the 24-month proportion
32with NEDA-3 was greater in both NTZ group (67%) and
33FNG group (42%) than in INJ group (35%) (p B 0.016);
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34 however, NTZ was superior to FNG in promoting the
35 attainment of NEDA-3 status (p = 0.034). In dataset B, the
36 24-month proportion with NEDA-3 was greater in NTZ
37 group (75%) and FNG group (67%) than in INJ group
38 (40%), but the small cohort sizes most likely prevented the
39 detection of any statistically significant difference. Our
40 study provides real-world evidence that NTZ was more
41 effective than both FNG and INJ in non-responders, while
42 it could seem that, in highly active treatment-naives, NTZ
43 was as effective as FNG and both were superior to INJ.4
45 Keywords Multiple sclerosis  Propensity score  NEDA 
46 Disease-modifying drugs
47 Introduction
48 Despite the increased availability of disease-modifying
49 drugs (DMDs) for treating relapsing-remitting multiple
50 sclerosis (RR-MS), there is not yet evidence-based algorithm
51 to drive specific decision-making about which is the optimal
52 treatment approach for non-responders to self-injectable in-
53 terferon beta (IFNB) and glatiramer acetate (GA) [1].
54 A ‘‘lateral’’ switch approach—i.e. changing treatment
55 from low-dose/frequency to high-dose/frequency IFNB, or
56 from IFNB to GA, or viceversa—is a commonly adopted
57 strategy in case of treatment failure or intolerability.
58 However, studies exploring the effectiveness of lateral
59 switch had different designs and provided conflicting
60 results [2–5].
61 An ‘‘escalation’’ approach—i.e. stepping up from a self-
62 injectable DMD to a more aggressive treatment with less
63 favorable risk:benefit ratio—has been reported to be more
64 effective than lateral switch in patients who did not respond
65 to IFNB or GA [6–9]. However, post-marketing studies
66aimed to explore which escalation strategy (NTZ or FNG)
67is more effective in non-responders provided mixed results
68[10–14]. However, these inconsistencies may be
69attributable to the heterogeneous treatment effectiveness in
70different treatment scenarios [15].
71Optimal treatment strategies have yet to be defined even
72in highly active treatment-naı¨ve patients with MS, where
73there are no data comparing the effectiveness of NTZ and
74FNG.
75Therefore, in this study we sought to explore the
76effectiveness of NTZ, FNG and first-line injectable DMDs
77in two different datasets of patients, i.e. non-responders to
78first-line therapy and highly active treatment-naı¨ve
79patients.
80Methods
81Study design
82This was an independent, multi-centre, post-marketing
83study. We retrospectively analyzed data of patients affec-
84ted by RR-MS and regularly attending eight tertiary MS
85Centres in Italy. Clinical and magnetic resonance imaging
86(MRI) data were prospectively collected and stored into an
87electronic database after approval by ethical committees
88and after obtaining an informed consent by each
89participant.
90This study was conducted in accordance with specific
91national laws and the ethical standards laid down in the
921964 Declaration of Helsinki and its later amendments. In
93no way this study did interfere in the care received by
94patients.
95Participants
96We considered two different patients’ datasets:
971. Non-responders (dataset A): patients who experienced
98either C2 relapses or 1 relapse associated with a
99residual Expanded Disability Status Scale (EDSS)
100score C2.0 in the previous year while on GA or IFNB,
101and, therefore, were submitted to start NTZ or FNG
102according to the Italian regulatory criteria [16]. We
103also included a group of patients who met the same
104criterion, but were switched from IFNB to GA or
105viceversa (INJ) because of patient preference’s or
106unavailability of an DMDs. Patients with previous
107exposure to immunosuppressive drugs were not con-
108sidered for this study.
1092. Highly active treatment-naı¨ves (dataset B): patients
110who had never been treated before with any DMD and
111had experienced C2 relapse in the previous year and
A44 1 Department of Neurology and Psychiatry, Sapienza
A45 University, Viale dell’Universita`, 30, 00185 Rome, Italy
A46 2 Department of Neuroscience, Reproductive Science and
A47 Odontostomatology, MS Clinical Care and Research Center,
A48 Federico II University, Naples, Italy
A49 3 MS Centre, Spedali Civili di Brescia, Montichiari, BS, Italy
A50 4 Department of Systems Medicine, MS Clinical and Research
A51 Center, Tor Vergata University, Rome, Italy
A52 5 Unit of Neurology and of Neurorehabilitation, IRCCS
A53 Neuromed, Pozzilli, IS, Italy
A54 6 Fondazione Policlinico Universitario A. Gemelli, Universita`
A55 Cattolica del Sacro Cuore, Rome, Italy
A56 7 Department of Neurosciences, S. Camillo Forlanini Hospital,
A57 Rome, Italy
A58 8 S. Filippo Neri Hospital, Rome, Italy
A59 9 S. Andrea Hospital, Rome, Italy
J Neurol
123
Journal : Large 415 Dispatch : 13-11-2016 Pages : 11
Article No. : 8343
h LE h TYPESET
MS Code : JOON-D-16-01462 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
112 C1 gadolinium (GD)-enhancing lesion on brain or
113 spinal cord MRI scan. These patients were submitted
114 to start NTZ or FNG as first treatment according to the
115 Italian regulatory criteria [16]. We also included a
116 group of patients who met the same criterion, but
117 started high-dose, high-frequency IFNB-1b or 1a (INJ)
118 because of patient preference’s or unavailability of an
119 alternative DMDs.
120 Assessments
121 All patients were followed for a 24-month observation
122 period. Clinical visits were scheduled at least every
123 6 months and included disability scoring by means of the
124 EDSS. Each patient underwent brain and spinal cord MRI
125 scan at baseline (within 30 days before DMD starting) and
126 at least every 6 months according to standardized proce-
127 dures using 1.5 Tesla magnets [17]. Scans were performed
128 before and after GD-DTPA injection, focusing on the
129 presence of radiological activity, i.e. GD-enhancement on
130 T1-weighted images, or the occurence of new hyperintense
131 lesions on T2-weighted images when compared to the
132 baseline scan.
133 Both pre-planned clinical examinations and MRI scans
134 were collected after 1 month of clinical stability and at
135 least 30 days after the last assumption of steroids.
136 Unscheduled visits and/or MRI scans were also performed
137 in case of relapse or any other clinically relevant condition,
138 including adverse events.
139 Outcome measure definition
140 As primary outcome, we estimated the proportions of
141 patients who had ‘‘no evidence of disease activity’’
142 (NEDA-3), a combined measure defined as absence of
143 clinical relapses, disability worsening, and radiological
144 activity [18]. NEDA has been recently proposed as a
145 principal aim in management of RR-MS because it leads to
146 better long-term outcomes [19, 20].
147 We also analyzed individually the subcomponents of
148 disease activity as secondary outcomes (time to relapse,
149 disability worsening, radiological activity).
150 A relapse was defined as any new neurological symp-
151 tom, not associated with fever or infection, lasting for at
152 least 24 h and accompanied by new neurological signs.
153 Disability worsening was defined as C1.5-point
154 increase (if baseline EDSS score was 0), C1.0-point
155 increase (if baseline EDSS score was\5.5), or C0.5-point
156 increase (if baseline EDSS score was C5.5) confirmed
157 6 months apart [21].
158 Radiological activity was defined as the occurence of
159 C1 GD-enhancing lesion or C1 new T2-hyperintense
160lesions. We decided to not consider enlarging T2-hyper-
161intense lesions since a previous study demonstrated a poor
162between-rater agreement for this metric under routine
163clinical setting [22].
164The occurrence of disability reduction, defined as a
1656-month sustained decrease of C1-EDSS point confirmed
166at the end of the 24-month follow-up, was also explored as
167tertiary outcome [23].
168Patients whose disability worsening or reduction started
169over the last few months of the pre-planned observational
170period had an additional follow-up to confirm the outcome
171reach.
172Statistical analysis
173All values were expressed as mean (SD) for continuous
174variables and as count (proportion) for categorical
175variables.
176For dataset A, we considered the following data at
177baseline (i.e. at DMD change after GA or IFNB failure)
178data: sex, age, time since first symptom, EDSS score,
179relapses in the previous year, absence/presence of GD-
180enhancement.
181For dataset B, we considered the following data at
182baseline (i.e. at treatment start): sex, age, time since first
183symptom, relapses in the previous year, EDSS score. In this
184latter dataset we did not include data on the baseline MRI
185scan since all patients had C1 GD-enhancing lesion as per
186eligibility criteria (see above).
187Between-group differences in baseline characteristics
188were tested using the Chi squared or the Kruskall-Wallis H
189tests, as appropriate, with Dunn’s post-hoc tests for pair-
190wise comparisons.
191Primary and secondary outcomes were formerly
192explored by unadjusted comparisons between the three
193groups using the Chi squared test.
194Since patients in both datasets were not randomized to
195treatment group, we performed a 1:1:1 ratio propensity
196score (PS)-based nearest neighbor matching procedure
197within a calliper of 0.05 and 0.1 for dataset A and B,
198respectively, without replacement [24]. According to the
199common-referent approach, two separate PS were derived
200using multivariable logistic regressions to estimate the
201conditional probability to receive NTZ vs. INJ and FNG vs.
202INJ, respectively; we then matched pairs of subjects with
203overlapping PS in NTZ and FNG groups [25]. The validity
204of PS matching was tested by analysis of standardized
205differences (jdj), with jdj[ 0.20 considered as imbalance
206[26].
207Primary, secondary and tertiary outcomes were then
208explored in matched samples by Cox proportional hazard
209regression models, adjusted for sex and age and stratified
210by matched cases [27]. As main time variable we used the
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211 length of the observation (in months) between the baseline
212 and the last visit over the 24-month period, or outcome
213 reach, whichever came first.
214 Post-estimation sensitivity analyzes were applied to
215 primary outcome in both datasets to test the sensitivity of
216 the matched models to an hypothetical confounder that
217 was either not collected or incompletely observed
218 [28, 29].
219 All two-tailed p values\0.05 were considered as sig-
220 nificant after correction for multiple comparison using the
221 Bonferroni–Holm procedure. Data were analyzed using the
222 Statistical Package for Social Sciences, version 16.0 (IBM
223 SPSS, Inc., Chicago, Ill., USA).
224 Results
225 Dataset A
226 Participants We collected data from 567 patients who did
227 not respond to GA or IFNB (n = 215 and n = 352,
228 respectively) after at least 12 months of continuous treat-
229 ment. Of them, 150 were switched to the alternative self-
230 injectable DMD type, 202 started FNG, and 215 started
231 NTZ (Fig. 1). Unadjusted comparisons of effectiveness
232 among the three different DMDs showed that: (1) NTZ was
233 superior to INJ in all outcomes (p\ 0.01); (2) FNG was
234 superior to INJ in all outcomes (p B 0.01), except one
235 (disability reduction, p = 0.2); (3) NTZ was superior to
236 FNG in achieving NEDA-3, suppressing radiological
237 activity and promoting disability reduction (p\ 0.05), but
238 there was no difference in terms of relapses and disability
239 worsening (p values[0.1).
240 We observed significant imbalance in pre-matching
241 baseline characteristics across treatment groups (Table 1).
242 Post-hoc tests indicated that patients escalated to NTZ were
243 younger and had more relapses in the previous year than
244 both INJ and FNG groups (p values\ 0.001). Patients in
245 NTZ group were also more disabled (p = 0.007) and were
246 more likely to have GD-enhancement at baseline scan
247 (p = 0.003) than those in INJ group. There were no dif-
248 ferences between FNG and INJ groups, except for higher
249 EDSS score in FNG group (p = 0.038).
250 Such between-group imbalance did not persist after the
251 matching procedure that retained 330 patients (110 per
252 group; Table 1). No covariate exhibited large imbalance
253 (jdj[ 0.20) in the re-sampled population (Fig. 2).
254 Primary outcome At follow-up, the proportion of
255 patients with NEDA-3 was greater in NTZ group (67%)
256 than both FNG (42%) and INJ (35%) groups (p values
257 B0.034). The proportion of FNG-treated patients with
258 NEDA-3 was greater than that of INJ group (42 vs. 35%,
259 p = 0.016). The Fig. 3 shows the description of different
260components of NEDA 3 in the PS-matched population at
261the end of the 24-month follow-up.
262Sensitivity analysis To alter the significant difference in the
263proportions with NEDA-3 between NTZ and INJ, the rel-
264ative risk estimate and between-group prevalence imbal-
265ance of an hypothetical unmeasured binary confounder
266should be either [5.0 and 40%, or [9.0 and 20%,
267respectively.
268To alter the significant difference in the proportions with
269NEDA-3 between FNG and INJ, as well as between NTZ
270and FNG, the relative risk estimate and between-group
271prevalence imbalance of an hypothetical unmeasured bin-
272ary confounder should be either[2.0 and 40%, or[5.0 and
27320%, respectively.
274Secondary outcomes (Table 2) The risk of relapse was
275lower in NTZ group when compared with INJ group
276[hazard ratio (HR) = 0.37, p\ 0.001] and FNG group
277(HR = 0.58, p = 0.048). The risk of relapse was also
278lower in FNG group when compared with INJ group
279(HR = 0.57, p = 0.048).
280There were no differences across treatment groups in
281risk of disability worsening (p values C0.18).
282The risk of radiological activity was lower in NTZ group
283when compared with both INJ group (HR = 0.28,
284p\ 0.001) and FNG group (HR = 0.48, p = 0.006). The
285risk of radiological activity was also reduced in FNG group
286when compared with INJ group (HR = 0.51, p = 0.006).
287Kaplan–Meier curves showing time to reach secondary
288outcomes are shown in Fig. 3.
289Tertiary outcome (Fig. 4) Although the proportion of NTZ-
290treated (9%) and FNG-treated patients (7%) with disability
291reduction was higher than that of INJ-treated patients (1%),
292we found no significant difference across treatment groups
293(p[ 0.07).
294Dataset B
295Participants We collected data from 216 highly active MS
296patients who started their first DMD following the diag-
297nosis. Of them, 93 started high-dose, high-frequency IFNB
298(IFNB-1b 250 mcg every other day, n = 42; IFNB-1a 44
299mcg thrice per week, n = 51), 63 started FNG, and 60
300started NTZ (Fig. 1). Unadjusted comparisons of effec-
301tiveness among the three different DMDs showed no
302between-group difference in disability worsening, mainly
303due to the low proportion of patients reaching the outcome
304(n = 30, 13%). We also found that (1) NTZ was superior to
cFig. 1 Study flow chart and proportion of patients reaching outcomes
before the propensity score matching procedure. Dataset A: non-
responders to interferon beta or glatiramer acetate; dataset B: highly
active treatment naives
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305 INJ in all remaining outcomes (p\ 0.01); (2) FNG was
306 superior to INJ in all remaining outcomes (p\ 0.05); (3)
307 there was no significant difference between NTZ and FNG
308 in proportion of patients with NEDA-3, relapses, and
309 radiological activity (p values [0.2), while NTZ was
310 superior to FNG in promoting disability reduction
311 (p = 0.03).
312 We observed significant imbalance in pre-matching
313 baseline characteristics across treatment groups (Table 3).
314 Post-hoc tests indicated that patients in INJ group had
315 shorter time since first symptom and lower EDSS score
316 than both FNG and NTZ groups (p values\0.05). Patients
317 in INJ group were also younger (p = 0.032) and had fewer
318 relapses in previous year than those ones in FNG group
319 (p = 0.002).
320 There was no difference between NTZ and FNG groups,
321 except for a greater number of relapses in previous year in
322 NTZ group (p = 0.038). Such between-group imbalance
323 did not persist after the matching procedure that retained
324 120 patients (40 per group; Table 3). No covariate exhib-
325 ited large imbalance (jdj[ 0.20) in the re-sampled popu-
326 lation (Fig. 2).
327 Primary outcome At follow-up, the proportion of patients
328 with NEDA-3 was greater in NTZ group (75%) and FNG
329 group (67%) than INJ group (40%), but none of the com-
330 parisons reached the statistical significance (p values
331 [0.06). Figure 3 shows the description of different com-
332 ponents of NEDA 3 in the PS-matched population at the
333 end of the 24-month follow-up.
334 Sensitivity analysis We did not perform the sensitivity
335 analysis in dataset B because there was no difference in
336 primary outcome across different treatment groups.
337 Secondary outcomes (Table 4) The risk of relapse was
338 lower only in NTZ vs. INJ group (HR = 0.29, p = 0.045),
339 while the comparison between FNG and INJ group was not
340 significant (HR = 0.48, p = 0.19). The risk of relapse did
341 not differ between NTZ and FNG (p = 0.99).
342There was no difference across treatment groups in risk
343of both disability worsening (p values[0.08) and radio-
344logical activity (p values[0.09).
345Kaplan–Meier curves showing time to reach secondary
346outcomes are shown in Fig. 3.
347Tertiary outcome (Fig. 4) Disability reduction was more
348frequently observed in NTZ group (20%) than in both INJ
349group (20 vs. 0%, p = 0.009) and FNG group (5%);
350however, this latter figure did not reach the statistical sig-
351nificance (p = 0.086). There was no difference between
352FNG and INJ in probability of disability reduction
353(p = 0.15).
354Discussion
355Quasi-randomized post-marketing studies have compared
356so far one DMD with another in MS people [6–14].
357However, neurologists can benefit from comparing the
358effectiveness of more than two appropriate treatment
359options. Therefore, here we sought to compare three
360treatment groups simultaneously by creating 1:1:1 PS-
361matched cohorts [24, 25, 29]. Moreover, we stratified the
362analyzes according to the past treatment history (non-re-
363sponders to self-injectable DMD and highly active treat-
364ment-naı¨ves) [16]. This allowed us to observe that, overall,
365highly active treatment-naı¨ves experienced better outcomes
366compared with non-responders, regardless of treatment
367allocation. This latter finding reinforces the concept of a
368greater effectiveness of whichever DMD in patients with
369RR-MS who started treatment at younger age, with milder
370EDSS and a more active disease [15].
371In line with literature data, unadjusted comparisons
372revealed that escalation to more active DMDs is better than
373lateral switch in patients who failed a GA or IFNB treat-
374ment [6–9], with NTZ superior to FNG in terms of NEDA-
3753, radiological activity, and disability reduction
Table 1 Dataset A: patients’ characteristics at baseline (i.e. at DMA change after GA or IFNB failure)
Whole sample Propensity-score matched sample
INJ FNG NTZ INJ FNG NTZ
N 150 202 215 110 110 110
Male sex, n (%) 49 (32.7) 54 (26.7) 64 (29.8) 33 (30.0) 35 (31.8) 27 (24.5)
Age, years 37.5 (8.7) 38.7 (9.7) 34.1 (9.3) 36.7 (8.8) 36.1 (9.2) 37.2 (9.4)
Time since first symptom, years 8.6 (6.4) 9.3 (7.2) 7.5 (5.3) 8.5 (6.3) 7.8 (5.8) 8.5 (5.8)
EDSS score 2.5 (1.2) 2.7 (1.3) 2.6 (1.2) 2.7 (1.3) 2.6 (1.1) 2.7 (1.1)
No. of relapse in previous year 1.3 (0.5) 1.4 (0.8) 1.7 (0.7) 1.4 (0.5) 1.4 (0.6) 1.4 (0.5)
Gadolinium-enhancement, n (%) 93 (62.0) 105 (52.0) 142 (66.0) 69 (62.7) 66 (60.0) 67 (60.9)
All values are mean (standard deviation), unless indicated otherwise
EDSS Expanded Disability Status Scale, FNG fingolimod, INJ self-injectable drugs, NTZ natalizumab
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376 [11–13, 23, 30]. The PS-adjusted analysis confirms that, in
377 our MS population, escalation to NTZ was the most
378 effective choice after failure treatment with GA or IFNB,
379 ensuring approximately a 2-fold (compared to INJ) and a
380 50% (compared to FNG) increased likelihood of NEDA-3
381 over a 24-month follow-up. The superiority of NTZ in the
382 non-responder dataset was mainly driven by its effective-
383 ness in reducing the risk of radiological activity and, to a
384 lesser extent, in suppressing relapses over INJ and FNG.
385 Notably, also FNG was superior over INJ in achieving
386 NEDA-3 status, suppressing relapses and radiological
387 activity. However, we found no difference across treat-
388 ments in terms of disability worsening and disability
389reduction. We may speculate that the low proportion of
390patients reaching these two outcomes (about 25 and 6% for
391disability worsening and reduction, respectively) compro-
392mised the statistical power for detecting such between-
393group differences [31, 32].
394In highly active treatment-naı¨ves, unadjusted compar-
395isons revealed that both NTZ and FNG were more effective
396than INJ in achieving the NEDA-3 status over the 24-month
397follow-up. The superiority of ‘‘second-generation’’ DMD
398(NTZ and FNG) over the ‘‘first-generation’’ DMD (high-
399dose, high-frequency IFNB) was mainly driven by a greater
400effectiveness on reducing the risk of relapse and radiological
401activity, while the overall small proportion of patients
Fig. 2 Standardized differences
(jdj) in baseline patients’
characteristics for pairwise
comparisons in dataset A and B
before and after the propensity
score matching procedure. DUR
time since first symptom, EDSS
Expanded Disability Status
Scale, GD? presence of
gadolinium-enhancement at
baseline scan, REL number of
relapses in the previous year
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402experiencing disability worsening (about 15%) prevented
403the detection of any between-group difference. We did not
404find any difference between NTZ and FNG groups in all
405(NEDA-3, relapses, radiological activity) but one outcome
406(disability reduction), thus confirming that NTZ can promote
407functional recovery in MS people [11, 13, 23, 30].
bFig. 3 Primary and secondary outcomes (no evidence of disease
activity and its components) investigated in propensity score-matched
subsamples (dataset A: 110 patients per group; dataset B: 40 patients
per group). p values are corrected using the Bonferroni–Holm
method. FNG fingolimod, INJ self-injectable drugs, NEDA-3 no
evidence of disease activity, NTZ natalizumab
Table 2 Cox regression models
(adjusted by propensity score
inverse weighting) to reach
secondary outcomes in non-
responders [re-sampled dataset
A, n = 330; patients per group,
n = 110], i.e. patients who
experienced C2 relapses or 1
relapse associated with residual
disability in the last year while
on glatiramer acetate or
interferon beta
n (%) reaching the outcome HR 95% CIs p*
Relapses
NTZ vs. INJ 22 (20%) vs. 48 (44%) 0.37 0.22–0.65 <0.001
FNG vs. INJ 32 (29%) vs. 48 (44%) 0.57 0.35–0.93 0.046
NTZ vs. FNG 22 (20%) vs. 32 (29%) 0.58 0.31–1.08 0.087
Disability worsening
NTZ vs. INJ 20 (18%) vs. 36 (33%) 0.58 0.33–1.02 0.18
FNG vs. INJ 27 (24%) vs. 36 (33%) 0.63 0.37–1.07 0.18
NTZ vs. FNG 20 (18%) vs. 27 (24%) 0.94 0.51–1.74 0.84
Radiological activity
NTZ vs. INJ 26 (24%) vs. 62 (56%) 0.28 0.17–0.46 <0.001
FNG vs. INJ 48 (44%) vs. 62 (56%) 0.51 0.33–0.80 0.006
NTZ vs. FNG 26 (24%) vs. 48 (44%) 0.48 0.28–0.81 0.006
FNG fingolimod, INJ self-injectable drugs, NTZ natalizumab
* By the Bonferroni–Holm correction for multiple comparisons
Fig. 4 Tertiary outcome (disability reduction) in propensity score-
matched subsamples (dataset A: 110 patients per group; dataset B: 40
patients per group). p values are corrected using the Bonferroni–Holm
method. FNG fingolimod, INJ self-injectable drugs, NEDA-3 no
evidence of disease activity, NTZ natalizumab
Table 3 Dataset B: patients’ characteristics at baseline (i.e. at treatment start)
Whole sample Propensity-score matched sample
IFN FNG NTZ IFN FNG NTZ
N 93 63 60 40 40 40
Male sex, n (%) 29 (31.2%) 23 (36.5%) 28 (46.7%) 13 (32.5%) 15 (37.5%) 16 (35%)
Age, years 30.3 (8.7) 33.4 (8.9) 29.4 (11.4) 32.2 (8.9) 32.1 (9.3) 30.4 (7.8)
Time since first symptom, years 1.8 (2.3) 3.6 (4.3) 3.2 (3.7) 2.1 (1.7) 2.3 (2.9) 2.2 (2.2)
EDSS score 1.8 (0.8) 2.5 (1.1) 2.8 (1.4) 2.1 (0.9) 2.1 (0.9) 2.1 (0.8)
No. of relapse in previous year 2.2 (0.6) 2.0 (0.7) 2.1 (0.8) 2.1 (0.5) 2.1 (0.6) 2.1 (0.7)
All values are mean (standard deviation), unless indicated otherwise
EDSS Expanded Disability Status Scale, FNG fingolimod, INJ self-injectable drugs, NTZ natalizumab
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408 Unfortunately, the PS-based re-sampling of dataset B
409 resulted in small cohort sizes and, therefore, we cannot
410 completely rule out that the borderline p values observed for
411 most comparisons are due to the low statistical power.
412 However, we are aware that the use of NTZ or FNG as first
413 treatment option is restricted by enrolment criteria in Italy
414 [15], making difficult to reach large sample sizes even in a
415 multicentre observational study.
416 The performance of FNG, better in highly active treat-
417 ment-naives than in non-responder ones, is only partially
418 surprising. Although the European Medicines Agency
419 (EMA) denied registration of FNG as first-line therapy, in
420 United States the Food and Drug Administration (FDA)
421 allowed prescription of FNG as first-line DMD in relapsing
422 MS. Furthermore, the successful FREEDOMS and
423 TRANSFORMS trials mainly enrolled patients without any
424 previous treatment history (more than 50%), thus sup-
425 porting its use as first treatment rather than second-line
426 option [33, 34].
427 In conclusion, we provide real-world data comparing
428 effectiveness of widely used DMDs in non-responders to
429 IFNB or GA and in highly active treatment naives. Per-
430 centages of patients with NEDA-3 widely varied even
431 within the same DMD according to previous treatment
432 history, especially in FNG-treated patients. However, our
433 study is only hypothesis-generating and suffers from sev-
434 eral limitations, as the small sample size of some treatment
435 groups (as discussed above), comparison of patients in
436 different treatment era, lack of randomization, and hidden
437 biases that were only partially dealt with sensitivity
438 analyzes.
439 On the other hand, we adopted robust statistical models
440 to enhance the validity of our findings and to provide a
441 minimally biased picture of the real-world clinical expe-
442 rience in the newer treatment era.3
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Table 4 Cox regression models
(adjusted by propensity score
inverse weighting) to reach
secondary outcomes in highly
active treatment-naives [re-
sampled dataset B, n = 120;
patients per group, n = 40], i.e.
patients who were never treated
before with any disease-
modifying drugs and
experienced C1 relapse in the
last year and 1C gadolinium-
enhancement at brain or spinal
cord scan
n (%) reaching the outcome HR 95% CIs p*
Relapses
NTZ vs. INJ 5 (12%) vs. 17 (42%) 0.29 0.11–0.81 0.045
FNG vs. INJ 8 (20%) vs. 17 (42%) 0.48 0.20–1.12 0.19
NTZ vs. FNG 5 (12%) vs. 8 (20%) 0.99 0.25–3.99 0.99
Disability worsening
NTZ vs. INJ 2 (5%) vs. 11 (27%) 0.18 0.04–0.82 0.081
FNG vs. INJ 4 (10%) vs. 11 (27%) 0.39 0.12–1.25 0.22
NTZ vs. FNG 2 (5%) vs. 4 (10%) 0.40 0.08–5.32 0.37
Radiological activity
NTZ vs. INJ 9 (22%) vs. 22 (55%) 0.42 0.19–0.93 0.096
FNG vs. INJ 11 (27%) vs. 22 (55%) 0.50 0.24–1.05 0.13
NTZ vs. FNG 9 (22%) vs. 11 (27%) 0.99 0.38–2.57 0.99
FNG fingolimod, INJ self-injectable drugs, NTZ natalizumab
* By the Bonferroni–Holm correction for multiple comparisons
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